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Background:  Two  transport  media,  PreservCyt  and  SurePath,  are  widely  used  for  cervical  cytology  screen-
ing. There  are  concerns  that  they may  perform  differently  for HPV  testing.
Objectives:  A  comparison  of the performance  of  six  different  HPV  tests  in  SurePath  and PreservCyt  in a
referral  population  using  two samples  from  each  woman.  The  primary  goal  was  to  compare  the perfor-
mance  of each  test  in  the  two  media.  Comparisons  between  assays  and  viral  load  comparisons  between
media  were  secondary  aims.
Study  design:  Two  cervical  samples  were  collected  in  random  order  at the  same  visit  in women  with
abnormal  cytology.  One  sample  was  placed  in  20 ml of PreservCyt  and  the  other  in  10 ml  of  SurePath.
Aliquots  were taken  for 4  DNA based  tests:  digene  HC2  High-Risk  HPV  DNA  Test,  Abbott  Realtime,  BD
Onclarity  and  Genera  PapType,  an  RNA  based  test—:  Hologic  Aptima  and  a protein  test:  OncoHealth.
Results:  630  sample  pairs  were  included  in  the  analyses.  For  all tests  except  the  protein  test  sensitivities
were  in  excess  of 90% for CIN2+  and  95%  for CIN3+  for both  media  and  with no  signiﬁcant  differences
except  for a lower  sensitivity  for CIN2+  of  Aptima  in SurePath  (93%  vs  98%,  P  =  0.005).  Speciﬁcity  for  <CIN2
was  signiﬁcantly  better  in  Surepath  for HC2,  RealTime  and  Aptima,  and generally  lower  relative signal
strengths  were  seen  with  SurePath  except  for  Onclarity,  especially  when  it was  the  second  sample.
Conclusions:  We  found  similar  sensitivity  for CIN3+  in PreservCyt  and SurePath  for  5  nucleic  acid  tests  in
the two  media  in  a referral  population,  but  signal  strength  and  positivity  rates  were  lower  in  SurePath
except  for the  Onclarity  test. These  results  need  to  be  replicated  in  a screening  population.
© 2016  The  Authors.  Published  by  Elsevier  B.V.  This  is  an open  access  article  under  the  CC  BY  license. Background
Two liquid-based cytology (LBC) systems are commonly used:
hinPrep using PreservCyt transport medium (Hologic Inc., Marl-
orough, MA)  and SurePath (Becton Dickinson, Sparks, MD)  using
urePath Preservative Fluid. Slide preparation procedures from
hese media are different [1,2]. Cells are normally collected using
 Cervex-Brush (Rovers Medical Devices, Oss, Netherlands) but in
reservCyt cells are rinsed into the medium, dispersed by vortex-
ng, and transferred to a microscope slide after vacuum ﬁltration. In
urePath, the detached head of the brush is placed in the medium.
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After initial centrifugation cells are resuspended, put through a
density gradient centrifugation with sampling of the pellet to make
the slide. The performance of both systems for cytology is compa-
rable [1,3].
An advantage of LBC is that additional tests, notably HPV,
can be run from a single sample, although only PreservCyt is
approved by the FDA for this. Unlike PreservCyt, SurePath con-
tains formaldehyde to preserve cell morphology and cross-linkage
between protein and nucleic acid can occur which can make DNA
undetectable and reduce DNA yield. This is partially reversible
using proteinase K (PK) digestion and/or heat treatment prior to
nucleic acid puriﬁcation [4–6]. It is currently unclear whether such
treatment can provide sufﬁcient native HPV DNA/RNA from indi-
vidual cervical samples for different HPV assays.
The majority of early studies of HPV testing in a medium also
suitable for cytology have been conducted using Qiagen’s digene
nder the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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Fig. 1. CONSORT diagram of patient enrolment and
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3. Study designig. 2. Sensitivity and speciﬁcity for CIN2+ (with 95% CIs) by HPV test and transport
edium. Solid shapes show PreservCyt and open shapes are for SurePath.C2 High-Risk HPV DNA Test (HC2) in PreservCyt. In a study of
72 SurePath and 1033 PreservCyt screening samples in different
omen Zhao et al. found no signiﬁcant difference in sensitivity and number with HPV testing by different tests.
speciﬁcity for the detection of CIN2+ by HC2 [7]. In a Danish study
of 5064 screening samples the positivity rate was  found to correlate
moderately well (kappa ≥0.60) between four assays (HC2 (Qiagen),
Cobas (Roche), CLART (Genomica) and Aptima (Hologic)) using
SurePath and multiple testing on one sample from each woman [8].
In another study of 367 women  with abnormal cytology this group
reported similar sensitivities for these four assays [9]. The UK Sen-
tinel Sites study of 10,051 women referred with borderline or mild
dyskaryosis showed a higher overall HPV positivity rate in Preserv-
Cyt than SurePath (68.7% vs 61.7%, p < 0.0001). However this may
be confounded by site as all but one site used only one medium and
the site using both media found no signiﬁcant difference in positiv-
ity rates [10]. To our knowledge, there has not been a comparison
of the performance of different HPV assays using PreservCyt and
SurePath samples collected from the same woman.
2. Objective
The objective of this study was a comparison of the perfor-
mance of different HPV testing assays in SurePath and PreservCyt
in a routine clinical setting. We  used a colposcopy referral popu-
lation and compared six HPV assays using two  samples from each
woman—one collected in PreservCyt and the other in SurePath. Our
primary goal was to compare the performance of each test in the
two media. Comparisons between assays were secondary aims.The study was conducted in the Colposcopy Unit of St. Mary’s
Hospital, London among women who  had been referred with an
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bnormal screening result within three months and never treated
or CIN. All women provided written informed consent.
Two cervical samples were collected with Cervex-Brushes
mmediately prior to colposcopic examination in accordance with
he European guidelines for quality assurance with cervical can-
er screening [11]. To minimise bias, the order of use of transport
edium was randomly assigned (1:1). One brush was agitated in
 vial containing 20 ml  of PreservCyt. The other brush head was
emoved and deposited in a vial containing 10 ml  of SurePath. All
amples were stored at 4 ◦C and transferred within two weeks of
ollection to the laboratory at the Wolfson Institute of Preventive
edicine, where HPV testing was performed.
Within one day of receipt in the laboratory, samples were
armed to room temperature, agitated for 60 s and aliquotted into
 ﬁxed order set of tubes, appropriate for six assays. This was
seudo-randomised to vary the aliquot assigned to each assay by
sing one of four dispensing patterns (left to right, right to left, cen-
re to right then centre to left, centre to left then centre to right).
amples were only identiﬁable to laboratory staff by participant
umber. All pathology was reviewed by M.S. who  was blinded to
esults and participant information.
. Laboratory methods
Sample storage before testing, aliquot volumes and positiv-
ty cut-off values were all in accordance with the manufacturers’
nstructions (Table 1). No tests were done on post-gradient pellets.
Manufacturers use ‘Invalid’ or ‘Indeterminate’ to denote failed
esults including when a whole plate or run fails. We  refer to all as
Failed’ results in this paper.
.1. Assays
.1.1. DNA based
digene HC2 High-Risk HPV DNA Test: the QIAsymphony auto-
mated platform was used for nucleic acid extraction with
the DSP AXpH DNA Kit (Qiagen, Hilden, Germany). This
consensus DNA test detects a panel of 13 high-risk HPV
types (16,18,31,33,35,39,45,51,52,56,58,59,68). PreservCyt and
SurePath samples were processed using different protocols:
PC AXpH hc2 V1 DSP protocol and a modiﬁed SP2000 V1 DSP
protocol including PK digestion and extended heated lysis time
(provided by Qiagen for research purposes only) respectively
[12]. 4 ml  PreservCyt or 0.5 ml  of SurePath diluted in 2 ml  of
deionised water were used. The resulting eluates (60 l) were
dispensed into a 96 well microplate for manual testing. Signal
strength was measured in Relative Light Units (RLU) compared
to a reference of approximately 5000 HPV copies.
The Abbott RealTime High-Risk HPV assay used the m2000 pro-
cessing System (Abbott Molecular, Abbott Park, Illinois) for the
detection of 14 high-risk HPV types, utilising Abbott reaction
vessels as sample input tubes. Types 16 and 18 are individually
reported. The remaining 12 high-risk types are reported together
as a pool (31,33,35,39,45,51,52,56,58,59,66,68).
The Becton Dickinson Onclarity HPV Assay using the BD Viper LT
System is a real-time PCR based DNA test which detects 14 high-
risk HPV types. Types 16,18,31,45,51,52 are detected individually.
The remaining eight high-risk types are reported in three groups:
(33,58), (35,39,68) and (56,59,66). A 0.5 ml  aliquot of thoroughly
vortexed SurePath or PreservCyt was added to 1.7 ml  of a pro-
prietary HPV diluent. A heat step was employed to ensure that
exfoliated cells were lysed and the sample homogenized prior to
extraction of sample DNA [4,5].
The Genera PapType Test is a semi-automated, bead-based
multiplex full genotyping DNA assay for 14 high-risk HPVirology 82 (2016) 145–151 147
types (16,18,31,33,35,39,45,51,52,56,58,59,66,68) and two low-
risk HPV types (6,11). The Sirocco platform (Genera Biosystems,
Scoresby, Australia) was  used. Prior nucleic acid extraction was
done using the Abbott m2000sp instrument [13]. Only high-risk
types were considered positive in this study. The assay measure
is derived from ﬂow cytometry and reported as S (signal). Type
speciﬁc cut-offs were used (Table 1).
4.1.2. RNA based
• The Hologic Aptima HPV assay is based on target capture,
transcription-mediated ampliﬁcation and hybridization protec-
tion for the detection of E6/E7 mRNA expression of 14 high-risk
HPV types (16,18,31,33,35,39,45,51,52,56,58,59,66,68). A con-
sensus result for positivity to other high-risk types was provided.
The Direct Tube Sampling platform was  used. Typing for 16 and
18/45, available as a reﬂex test, was not done here. The SurePath
sample was treated with PK at 65 ◦C for 2 h before being assayed
manually. The cut-off was speciﬁed to be 0.5 of the ratio of the
intensity to the reference standard.
4.1.3. Protein based assay
• OncoHealth (OncoHealth, San Jose, California) protein test is a
direct E6/E7 HPV Whole-Cell ELISA carried out in microtitre wells
and is based on detection by non-type speciﬁc HPV E6 and E7
monoclonal antibodies [14]. Relative Optical Density (ROD) was
used compared to a reference value of 0.35.
For all HPV tests except HC2 both samples were processed using
an identical assay workﬂow. (To distinguish this from workﬂow
associated with sample preparation). Test details using Preserv-
cyt for HC2, Onclarity, RealTime,  PapType and Aptima have been
described previously [13,15–17].
5. Statistical analysis
The primary analyses consisted of paired comparison of the
two samples from each woman. For some assays confounding was
observed related to the order in which the sample was taken. Subse-
quently additional non-paired analyses by the Wilcoxon Ranksum
test and a robust L1 based linear model with allowance for test order
were also conducted [18]. A measure of viral load (log(1 + relative
intensity units (RIU)) or minus Ct values) was  used to perform
correlation and regression analyses with adjustment for sample
order for paired samples within each test. Here RIU refers to the
signal strength of the sample compared to a standard (Table 1).
Non-ampliﬁed samples for Onclarity and RealTime were given a Ct
value of 40 and signal strength 0 for Aptima. SAS (version 9.2) and
R (version 3.2.2) were used. All statistical tests were two-sided and
a p-value of 0.05 were accepted as statistically signiﬁcant.
6. Results
The analysis was  based on 630 sample pairs obtained from 652
participating women. Reasons for drop out are shown in Fig. 1.
The median age was 30.0 years (IQR = [27.0, 34.8]). HC2 was intro-
duced during the study, and only the last 344 sample pairs were
tested. There were no failed results for HC2, Onclarity, OncoHealth
or RealTime. For PapType one sample pair was not tested with either
medium and 46 tests (44 sample pairs) failed (16 from PreservCyt,
30 from SurePath). For Aptima there were 22 failed tests (17 sample
pairs; 10 in PreservCyt, 12 in SurePath).Entry cytology was  borderline dyskaryosis 193(30.6%), mild
dyskarosis 380(60.4%), moderate dyskaryosis 37(5.9%) and severe
dyskaryosis or glandular abnormality 20(3.2%). A total of
176(28.0%) histology results were CIN2 or worse, including
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Table 1
HPV assays performed, positivity cut-off and aliquot volume.
Test Positivity Cut-offa,b Aliquot volume (ml)
PreservCyt SurePath
HC2 ≥1 RLU 4.0 0.5
RealTime  ≤32 Ct 0.5 0.5
Onclarity ≤34.2 Ct 0.5 0.5
PapType HPV58 ≥ 0.0004HPV68 ≥ 0.0003All others ≥ 0.0002 0.5 0.5
Aptima ≥0.5 RIU 1.0 0.5
OncoHealth ≥0.35 OD 1.0 1.0
a For all tests except RealTime  and Onclarity, units are ratio of signal strength to reference standard.
b RLU, relative light units; Ct, cycle threshold; RIU, relative intensity units; OD, optical density.
Table 2
Overall positivity, sensitivity for CIN3+ and CIN2+, speciﬁcity for < CIN2 and agreement for different tests and transport media.
Overall positivity (%) Sensitivity Speciﬁcity
CIN3+ (N = 96)c CIN2+ (N = 176)c <CIN2 (N = 454)c
HC2 (N = 344)
PreservCyt 289 (84) 0.98 0.97 0.21
SurePath 269 (78) 0.98 0.96 0.28
Agreement (%) 89.5 95.6 94.5 87.7
Discordanta 28 vs 8 1 vs 1 3 vs 2 25 vs 6
P-valueb 0.001 1 1 0.001
RealTime  (N = 630)
PreservCyt 476 (76) 0.99 0.95 0.32
SurePath 447 (71) 0.97 0.91 0.37
Agreement (%) 93.8 95.8 94.3 93.6
Discordanta 34 vs 5 3 vs 1 8 vs 2 26 vs 3
P-valueb 2.4 × 10−6 0.62 0.11 1.5 × 10−5
Onclarity (N = 630)
PreservCyt 486 (77) 1.00 0.97 0.31
SurePath 494 (78) 1.00 0.97 0.29
Agreement (%) 97.1 100 100 96
Discordanta 5 vs 13 0 vs 0 0 vs 0 5 vs 13
P-valueb 0.10 1 1 0.10
PapType (N = 585)
PreservCyt 465 (79) 0.96 0.93 0.26
SurePath 469 (80) 0.96 0.94 0.25
Agreement (%) 93.5 93.4 95.8 92.6
Discordanta 17 vs 21 3 vs 3 3 vs 4 14 vs 17
P-valueb 0.63 1 1 0.72
Aptima  (N = 613)
PreservCyt 476 (78) 100 0.98 0.30
SurePath 446 (73) 0.99 0.93 0.35
Agreement (%) 90.2 100 95.4 88.1
Discordanta 45 vs 15 0 vs 0 8 vs 0 37 vs 15
P-valueb 1.3 × 10−4 1 0.01 0.003
OncoHealth (N = 630)
PreservCyt 356 (57) 0.58 0.60 0.45
SurePath 301 (48) 0.55 0.52 0.54
Agreement (%) 55.4 46.9 49.4 57.7
Discordanta 168 vs 113 27 vs 24 51 vs 38 117 vs 75
P-valueb 0.001 0.78 0.203 0.003
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ba PreservCyt+/SurePath- vs SurePath+/PreservCyt-.
b McNemar’s test.
c Number refers to the whole population of N = 630. See Fig. 1 for reduced numbe
4(15.0%) cases of CIN3 or CGIN and 2(0.3%) cases of invasive cancer.
Supplementary Table S1).
Overall positivity, sensitivity for CIN3+ and CIN2+ and speciﬁcity
or <CIN2 for the different tests and transport media are shown in
able 2. Sensitivity and speciﬁcity for CIN2+ are further illustrated
n Fig. 2 and CIN3+ in Supplementary Fig. 1. All tests showed high
ensitivities for both samples in excess of 90% for CIN2+ and 95%
or CIN3+, except OncoHealth which had low sensitivity in both
edia. A matched-pairs analysis indicated no signiﬁcant difference
etween media for sensitivity for either CIN2+ or CIN3+ for any test, HC2, PapType and Aptima.
except for Aptima which was  slightly less sensitive in SurePath (98%
vs 93%, P = 0.005). However, there were differences in speciﬁcity
with signiﬁcantly higher speciﬁcities for HC2, RealTime, Aptima and
OncoHealth in SurePath. Although showing some predictive ability
above chance in PreservCyt, the OncoHealth test was substantially
and signiﬁcantly less sensitive than all other tests (≤60% for both
media for both CIN2+ and CIN3+), but was  more speciﬁc than the
other assays. There was  no signiﬁcant difference however with the
OncoHealth assay between media.
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Table  3
(A) Median signal strength (viral load) by test, transport medium and order of the test for samples from women positive for at least one medium using the speciﬁed test.
Units  are the ratio to a reference sample except for RealTime and Onclarity which are CT values. Type speciﬁc results for HPV 16 and 18 (where available) are shown in the
lower  part of the table. (B) 2-sided P-values for comparisons between different media and order using unpaired comparisons by the Wilcoxon RankSum test for samples
positive for at least one medium.
(A) Median signal strength (RIU or CT)
Medium and order of sampling
HPV Test PreservCyt 1st PreservCyt 2nd SurePath 1st SurePath 2nd
HC2 235.03 292.80 90.54 53.08
RealTime  21.30 22.03 23.64 25.85
Onclarity 24.16 24.37 23.16 24. 32
PapType  30.53 27.43 25.79 19.54
Aptima 10.67 10.81 10.55 9.80
OncoHealth 1.04 2.10 1.00 1.78
RealTime  16 20.17 22.05 24.22 24.43
RealTime  18 23.09 21.90 23.12 26.91
Onclarity 16 25. 16 25.66 24.11 24. 75
Onclarity 18 27.42 25.79 25.46 26.63
PapType 16 28.43 32.28 27.83 19.88
PapType 18 13.97 5.76 13.67 11.25
(B)  Signiﬁcance levels (2-sided)
HPV Test PreservCyt 1st vs PreservCyt 2nd PreservCyt 1st vs SurePath 1st SurePath 1st vs SurePath 2nd PreservCyt 2nd vs SurePath 2nd
HC2 0.998 0.009 0.011 1.04e-07
RealTime  0.092 1.83 × 10−5 2.2 × 10−8 8.6 × 10−15
Onclarity 0.104 0.033 0.011 0.182
PapType 0.167 0.034 0.004 6.0 × 10−4
Aptima 0.313 0.094 0.012 4.7 × 10−7
OncoHealth 1.44 × 10−25 0.155 3.8 × 10−22 1.2 × 10−4
RealTime 16 0.029 1.9 × 10−4 0.038 2.0 × 10−5
RealTime 18 0.859 0.414 0.024 0.004
Onclarity 16 0.353 0.123 0.208 0.101
Onclarity 18 0.781 0.174 0.314 1.000
PapType 16 0.460 0.810 0.078 0.015
PapType 18 0.857 0.754 0.512 0.967
Table 4
Spearman’s  Correlation coefﬁcient and slope when SurePath values are regressed on PreservCyt values using L1 (robust) regression where values are either the log (1 + RIU
value) or (minus) Ct value and sample order is accounted for. (See methods section). One tailed p-values compare observed slope to unity (no difference in viral load between
media).
HPV Test Na Spearman’s  (95% CI) Slope (95%CI); P-value (vs unity)
HC2 297 0.814 (0.771, 0.849) 0.966 (0.875, 1.057); p = 0.231
RealTime 481  0.724 (0.678, 0.764) 0.823 (0.724, 0.923); p = 2.5 × 10−4
Onclarity 499 0.884 (0.8.64, 0.902) 0.841 (0.778, 0.903); p = 3.0 × 10−7
PapType 486 0.756 (0.715, 0.792) 0.871 (0.780, 0.963); p = 0.003
Aptima 491 0.683 (0.633, 0.727) 0.676 (0.514, 0.838); p = 4.5 × 10−5
OncoHealth 469 −0.133 (−0.221, −0.043) 0.242 (0.121, 0.362); p < 2.010−16
RealTime  16 159 0.574 (0.460, 0.670) 0.653 (0.400, 0.906); p = 0.004
RealTime  18 55 0.660 (0.478, 0.787) 0.649 (0.242, 1.056); p = 0.046
Onclarity 16 161 0.838 (0.786, 0.879) 0.827 (0.677, 0.977); p = 0.012
Onclarity 18 57 0.890 (0.820, 0.934) 0.833 (0.561, 1.105); p = 0.114
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PapType 18 88 0.748 (0.
a Positive at least for one test.
Signal strength (viral load estimate) differed by transport
edium and test order (Table 3). Little difference was seen between
he two media when used as a ﬁrst test, except for substantially
igher values for RealTime  in SurePath (P < 2 × 10−5) and HC2 in
reservCyt (P = 0.009). For HC2 this probably reﬂects a larger sam-
le volume for PreservCyt. Signiﬁcantly higher values were seen for
reservCyt (vs SurePath) when both were used as a second sample
specially for HC2—again with the exception of Onclarity. Type spe-
iﬁc results for HPV 16 and 18 for RealTime, Onclarity and PapType
ave a similar pattern (Table 3).
PreservCyt values were not statistically signiﬁcantly different
etween the ﬁrst versus second samples in all cases except for
ncoHealth where they were substantially lower in the second
ample (Table 3). For SurePath, signiﬁcant differences between the.826) 0.942 (0.839, 1.046); p = 0.137
.828) 0.914 (0.735, 1.094); p = 0.175
ﬁrst and second sample were seen for all tests, but the second sam-
ple gave higher levels for RealTime  and Onclarity and lower levels
for the other tests. For HC2 the RLU values were much lower in the
second sample for SurePath, possibly due to the smaller sample
volume assayed.
The correlation between the signal strength measurements for
the two  media for each test is shown in Table 4. While correlations
for the tests in the two media were quite good, except for the Onco-
Health test, the slopes were signiﬁcantly less than unity for all tests
except HC2 where it was 0.966 (p = 0.23), indicating that the values
are generally higher for PreservCyt. Minimal correlation between
media could be seen for the OncoHealth test. A fuller presentation
of the differences between the two media is shown as scatterplots
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or each test in Supplementary Figs. S2–S7, in which the order of
he test is also depicted.
. Discussion
Our results indicate that similar sensitivities and speciﬁcities
an be achieved with either PreservCyt or SurePath for 5 of the
 HPV tests, provided that the manufacturer’s recommended pre-
reatments are observed. Some loss of sensitivity for CIN2 was
een for RealTime and Aptima in SurePath, but this was  minimal
or CIN3+. The largest differences were seen for speciﬁcity which
as generally better for SurePath, especially for HC2, RealTime  and
ptima. This is likely to also be true for primary screening but direct
eriﬁcation in this setting is needed. Poor performance was  seen
or the OncoHealth protein test in both media. This protein-based
est however is known to be less stable in alcohol and a second
eneration test has been developed since this study was carried
ut.
The failure rate for PapType was relatively high (3.6%, 45/1260).
o speciﬁc reason could be identiﬁed, but this was a prototype test
ith the complexity of full typing, so improvements are likely in
he future. The failure rate was 1.3% for Aptima, but there were no
ailures for any other tests.
The differences between tests were greater for the second than
he ﬁrst sample, illustrating the differences in a true diagnostic sit-
ation where only a ﬁrst sample would be used. This highlights
he need for an adequate sample and may  be a factor in the dis-
ordant results between assays as found by Rebolj et al. [8]. The
urePath vial contained 10 mls  and PreservCyt 20 mls  of transport
edium. Thus the concentration of cells in SurePath is greater than
n PreservCyt. The only test where the amount of DNA in the tested
ample would be expected to be the same in both media would be
he Aptima test where the aliquot volume was 1 ml  of PreservCyt
nd 0.5 ml  of SurePath. All others tests except HC2 used an equal
liquot volume (0.5 ml)  and would lead to less DNA in the Preserv-
yt sample. For HC2 4 mls  were assayed from PreservCyt versus
.5 ml  from SurePath. However this had no measurable impact on
he results.
Although not of direct clinical relevance, comparison of the
uantitative measures of signal strength as a surrogate measure
f viral load provides additional insight into the comparative per-
ormance of the different tests in the two transport media. We
ecognise that there are several confounding factors to this measure
ncluding cell number and speciﬁc methods of measuring signal
trength. In general lower signal strength values were obtained for
urePath. The largest differences were seen for HC2 which could
artly be attributed to a smaller sample volume for SurePath.
Most HPV assays have been more fully optimized for PreservCyt,
hich has been in use for longer. An exception is the Onclarity
ssay, developed by the manufacturer of SurePath. The Onclarity
ssay uses a heat step in sample pre-processing for both sample
ypes and little difference between media was seen. At the time of
his study no HPV test manufacturer had an approved protocol for
heir assay in the SurePath medium and it is possible that this will
mpact on performance.
In summary this prospective study is the ﬁrst comprehensive
omparison of a range of HPV tests in the two most commonly
sed LBC transport media where two samples are taken from each
oman. No major differences in performance were seen when the
anufacturer’s protocols were used. These tests have all performed
ell in this referral population and although all appear suitable for
creening. They need to be validated using the Arbyn criteria in a
creening population [11].
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